Japan· JP-2399404F1033
インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］
A medicinal product containing インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］, registered in Japan by 日医工, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］
- Manufacturer
- 日医工
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］ in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFLIXABISamsung Bioepis NL B.V., Delft
- SwitzerlandFlixabi
- FinlandFlixabiSAMSUNG BIOEPIS NL B.V.
- United StatesAVSOLAAmgen, Inc
- BelgiumFlixabi 100 mgSamsung Bioepis NL
- SpainFLIXABI 100MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSamsung Bioepis Nl B.V.
- PolandFlixabiSamsung Bioepis NL B.V.
- United KingdomFlixabi 100mg powder for concentrate for solution for infusion vialsBiogen Idec Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Remicade, Remsima
- Liechtenstein · Remicade, Remsima
- Norway · Remicade, Remsima
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c7ce5cc9-c3ca-4186-94b2-9faa12e1d252 GET /v1/drugs/c7ce5cc9-c3ca-4186-94b2-9faa12e1d252?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2399404F1033",
"category": "注射薬",
"price_yen": 12662,
"generic_name": "インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］",
"product_name_jp": null,
"therapeutic_class": "2399",
"transitional_expiry": "R9.3.31まで"
}See everything about インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.